The present disclosure provides a method for analyzing glyeart-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.

In the present invention a method is provided for capillary electrophoresis-based (CE-based) comprehensive N-glycan analysis of urinary PSA. The method is useful for analysis of PSA glycans from urine and for diagnosis of PSA-related conditions.

A living plant can function as self-powered auto-samplers and preconcentrators of an analyte within ambient groundwater, detectors of the analyte contained therein. For example, a pair of near infrared (IR) fluorescent sensors embedded within the mesophyll of the plant leaf can be used as detectors of the nitroaromatic molecules, with the first IR channel engineered through CoPhMoRe to recognize analyte via an IR fluorescent emission and the second IR channel including a functionalized nanostructure that acts as an invariant reference signal.

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

The present teachings relate to methods, systems, and kits for analyzing a sample containing a glycopeptide of interest that can subject the glycopeptide of interest to a plurality of parallel deglycosylation reactions that differentially cleave the glycan, with the various products resulting from the deglycosylation reactions being differentially labeled (e.g., with isobaric and/or isomeric labeling reagents) to thereby produce labeled glycopeptides or labeled fragments of the glycopeptides. The products of the various deglycosylation reactions can then be mixed together and subject to LC-MS/MS using a single injection of the mixture. In accordance with various aspects, by associating the resulting mass spectral data with a particular deglycosylation reaction (e.g., based on the presence in the MS/MS data of product reporter ions associated with the particular differential labels), the methods and systems described herein can aid in the identification of the glycan structure

The presence of mild electrophiles, such as aldehydes, during the denaturation of glycoproteins or glycopeptides and subsequent enzymatic deglycosylation reduces artifacts in subsequent analyses of the glycans released from the glycoproteins or glycopeptides.

A centripetal microfluidic platform comprised of a microfluidics disc and a reader for testing LAL-reactive substances in fluid samples is provided. The microfluidic disc may comprise at least two testing areas wherein each testing area includes a reservoir portion for receiving at least one fluid sample. The disc may comprise a distribution network portion in fluid communication with the reservoir portion. Each distribution network portion may comprise a distribution network of at least four (4) channels, wherein each channel has a metering portion and at least one analysis chamber portion. The analysis chamber portion may comprise a mixing chamber for mixing samples and reagents and an optical chamber portion that is compatible with an optical reader. The metering portion may be sized to meter an aliquot of the fluid sample for analysis in the analysis chamber portion. At least one analysis chamber portion has at least one reagent isolated therein. The centripetal microfluidic platform further includes a reader for testing fluid samples within a microfluidic disc comprising an enclosure, an optical bench, a centripetal disc drive, and a controller. A method for testing at least one fluid sample for LAL-reactive substances is also provided.

The present invention relates to methods for creating isotopically-labeled glycans or glycoconjugates for use in the analysis of glycans, and compositions produced from such methods. The present invention also relates to the use of isotopically labeled glycans or glycoconjugates as standards in glycan identification and/or quantification methods. In one embodiment, the method of the present invention can be used to accurately determine the levels of glycans in a sample based upon the addition of a known quantity of a standard comprising isotopically-labeled glycans to the sample prior to analysis. In one embodiment, the present invention relates to a composition for an analytical standard comprising one or more isotopically-labeled glycans or glycoconjugates.

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.